Abstract
AbstractMalaria vaccine introduction in endemic countries is a game-changing milestone in the fight against the disease. This article examines the inequity in the global pharmaceutical research, development, manufacturing, and trade landscape. The role of inequity in hindering progress towards malaria elimination is explored. The analysis finds that transformational changes are required to create an equity-enabling environment. Addressing the inequity is critical to maximizing the public health impact of vaccines and attaining sustainability. Avenues to catalyze progress by leveraging malaria vaccines and messenger ribonucleic acid (mRNA) technology are discussed.
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. WHO. Malaria vaccine: WHO position paper – March 2022. Wkly Epidemiol Rec. 2022;97:60–78.
2. World Health Organization. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization. Geneva: World Health Organization; 2023.
3. Hamilton A, Haghpanah F, Hasso-Agopsowicz M, Frost I, Lin G, Schueller E, et al. Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries. Commun Med (Lond). 2023;3:144.
4. World Health Organization. WHO guidelines for malaria. Geneva: World Health Organization; 2023.
5. Volza. Global export import trade data of 209+ countries. Rehoboth BCH: Volza; 2023.